Illumina, Inc. (NASDAQ:ILMN) Receives $127.94 Consensus Price Target from Brokerages

Posted by Donna Armstrong on Feb 27th, 2026

Shares of Illumina, Inc. (NASDAQ:ILMN – Get Free Report) have been given an average recommendation of “Hold” by the nineteen research firms that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $127.9412.

A number of research analysts recently commented on ILMN shares. Zacks Research lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. UBS Group reiterated a “neutral” rating and set a $135.00 price target on shares of Illumina in a research report on Friday, February 6th. TD Cowen restated a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Piper Sandler decreased their target price on Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. Finally, Evercore set a $150.00 price target on shares of Illumina in a research report on Friday, February 6th.

Read Our Latest Report on Illumina

Illumina Price Performance

Shares of ILMN opened at $127.40 on Tuesday. The firm has a market capitalization of $19.48 billion, a price-to-earnings ratio of 23.38, a price-to-earnings-growth ratio of 2.33 and a beta of 1.45. The stock’s fifty day moving average is $135.13 and its 200-day moving average is $117.84. Illumina has a one year low of $68.70 and a one year high of $155.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08.

Illumina (NASDAQ:ILMN – Get Free Report) last announced its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the prior year, the firm posted $0.95 EPS. Illumina’s revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities analysts anticipate that Illumina will post 4.51 EPS for the current year.

Insider Buying and Selling at Illumina

In other news, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the sale, the insider directly owned 17,887 shares of the company’s stock, valued at $2,434,241.83. The trade was a 1.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Capital World Investors lifted its position in shares of Illumina by 20.0% in the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after acquiring an additional 3,331,542 shares in the last quarter. Invesco Ltd. boosted its position in shares of Illumina by 97.0% in the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after buying an additional 1,352,731 shares during the period. AQR Capital Management LLC grew its holdings in shares of Illumina by 55.3% during the second quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock valued at $313,290,000 after buying an additional 1,174,295 shares in the last quarter. Morgan Stanley raised its position in Illumina by 66.0% during the fourth quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock valued at $331,710,000 after buying an additional 1,005,474 shares during the period. Finally, Nordea Investment Management AB lifted its stake in Illumina by 2,792.2% in the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after acquiring an additional 911,843 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Illumina launched TruPath™ Genome and unveiled a NovaSeq X roadmap at AGBT, positioning the company to capture higher‑value whole‑genome and instrument upgrade demand. Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics
Positive Sentiment: Illumina highlighted customer breakthroughs using Connected Multiomics (spatial transcriptomics, epigenomics, proteomics), which supports higher‑margin consumable sales and strengthens clinical/research adoption narratives. Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics
Positive Sentiment: Takara Bio USA announced a collaboration with Illumina on a single‑cell spatial transcriptomics workflow presented at AGBT, expanding ecosystem partnerships and accelerating adoption in translational oncology and diagnostics. Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026
Positive Sentiment: Market research forecasts strong growth in preimplantation genetic testing (PGT) through 2030, supporting long‑term demand for NGS platforms and reagents that Illumina supplies. Preimplantation Genetic Testing Market Research and Global Forecast Report 2025-2030
Neutral Sentiment: Analysts and publications are comparing Illumina to competitors like Tempus (TEM), highlighting strong TEM revenue growth and AI oncology momentum—underscoring competitive risk but also validating the sector’s growth tailwinds. TEM vs. ILMN: Which MedTech Stock Offers Greater Upside?
Neutral Sentiment: A separate analyst piece reviews Illumina’s recent share rebound and longer‑term volatility, reminding investors to weigh valuation and execution risk despite the near‑term product news. Assessing Illumina (ILMN) Valuation After Recent Share Price Rebound And Longer Term Volatility

Illumina Company Profile

(Get Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.